TOT BIOPHARM International Company Limited, an investment holding company, engages in the research and development, manufacture, and marketing of anti-tumor drugs in the People's Republic of China. The company's principal drug candidate is TAB008 for the treatment of non-squamous non-small-cell lung cancer metastatic colorectal cancer, glioblastoma multiforme, ovarian cancer, cervical cancer, and hepatocellular carcinoma. It also offers TOZ309 for malignant brain tumor. Further, the company develops TAA013 for HER2+ breast cancer which is under Phase III clinical trial; TAE020 which is under preclinical trial for acute myeloid leukemia; TAB014 for wet age-related macular degeneration and is under Phase II clinical trial. In addition, it develops TAY018 for non-Hodgkin's lymphoma, myelodysplastic syndrome, acute myelogenous leukemia, and solid tumors; TAC020 for various solid tumors; TEP118 for biliary cancer, gallbladder tumors, metastatic cancer, non-small-cell lung cancer (NSCLC), and gastric cancer; TOM312 for cancer and HIV-associated cachexia; TIC318 for epithelial-derived ovarian cancer, small-cell lung cancer, head and neck squamous cell carcinoma, testicular tumors, malignant lymphoma, cervical cancer, bladder cancer, and NSCLC; TVP211 and TID214 for solid tumors; and TIO217 for gastrointestinal tumors. TOT BIOPHARM International Company Limited was incorporated in 2009 and is headquartered in Suzhou, the People's Republic of China.
TOT BIOPHARM International Dividend Announcement
• TOT BIOPHARM International does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on TOT BIOPHARM International dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.
TOT BIOPHARM International Dividend History
TOT BIOPHARM International Dividend Yield
TOT BIOPHARM International current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing TOT BIOPHARM International stock? Use our calculator to estimate your expected dividend yield:
TOT BIOPHARM International Financial Ratios
TOT BIOPHARM International Dividend FAQ
1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.
2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.
3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.
4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.
5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Place an order: Use the brokerage's trading platform to place an order to buy TOT BIOPHARM International stock.
Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.